CBDbrands.com +1(561) 325-0482 info@CBDbrands.com 1 - - PowerPoint PPT Presentation

CBDbrands.com • +1(561) 325-0482 •info@CBDbrands.com

1

To the extent any statements contained in this presentation of CBD Brands, Inc. (the “Company”) contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs

• f, and information currently available to, the company’s management as well as estimates and assumptions made by the

company’s management. These statements can be identified by the fact that they do not relate strictly to historic or current

• facts. When used in this presentation the words “estimate,” “expect,” intend,” believe,” plan,” “anticipate,” “projected”

and

• ther words or the negative of these terms and similar expressions as they relate to the company or the company’s

management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company’s industry, its

• perations and results of operations and any businesses that may be acquired by the company. Should one or more of these

risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance or

• achievements. Except as required by applicable law, including the security laws of the United States, the company does not

intend to update any of the forward-looking statements to conform these statements to actual results.

2

Forward-Looking Statement

The CBD market is difficult to understand. Patients lack reliable resources to turn to for help in understanding the benefits of CBD, choosing the right formulations and products for their family’s needs, and knowing who to trust for their purchase.

The Market’s Problem Is Our Opportunity

Reliability

Trustable resource for news, information, and unbiased product reviews.

Drug Development

Effective medical advancements through innovative drug development

Seed-to-Need

Tracking the source and only using the highest-grade CBD will increase quality and safety for consumers.

3

The endocannabinoid system plays an important role in the immune response of

• ur skin, including: regulation of cell

growth and wound healing, skin homeostasis, and release of inflammatory mediators.

4

Both CB1 and CB2 receptors have been found throughout the skin, making topical applications perfect for treating a rangeof conditions, including:

Underlying Science

Cannabinoid receptors are found throughout the skin

Joint Pain Arthritis Pain Muscle Pain Inflammation Psoriasis Eczema Itchy Rashes Neck and Back Pain Contact Dermatitis Acne

Full-Spectrum CBD: Made with the entire plant and does contain trace amounts of

• THC. To bypass this, many companies produce what is known as CBD isolate: a pure

crystalline powder that contains 99% pure CBD. CBD Isolate: All the plant matter that is contained in the hemp plant is removed through a purification process that follows the extraction process. What remains is a final product that only contains CBD without any trace amounts of THC. Broad-Spectrum CBD: This is simply a CBD product with all the benefits of full spectrum products (terpenes, minor cannabinoids, and other natural parts of the cannabis plant) but without the THC.

CBD Comes In Many Forms

5

Business Divisions

Brands/Products

We are actively developing an innovative line of high-quality CBD- infused suncare, skincare, cosmetics, nutraceuticals, and wellness products.

CDB Clinics

We plan to open specialty CBD retail stores throughout the state of Florida begninning in 2019. We intend to expand nationwide through acquisitions and expansion.

Drug Development

We plan to run nutraceutical clinical trials towards proof of concept and FDA approval.

6

CBD Brands is a functional wellness and natural health products company. With a tireless devotion to quality, sourcing, and customer care, our goal is to harness and research the scientifically-backed health benefits of CBD such as pain relief and muscle relaxation to help the population live a more fulfilling life through a variety of forthcoming products.

Our First Brands

7

We have developed a CBD-infused sunscreen with broad-spectrum SPF protection under the CaniSun™ brand name. We recently launched a suncare line of SPF 30, SPF 55 and SPF 50 face lotion. We have completed lab testing for CBD solubility – infusing clear, colorless, odorless, and 99.5% pure CBD isolate with three different FDA approved suncare actives (homosalate, octisalate and octocrylene).

8

Lipbalm Sunscreen Spray Sunscreen Moisturizing Body Lotion

Product Line

9

Addition of Ingredients Batch Mixing Tube Fill Lab Testing for Quality

Quality Lab Process

10

Currently in development, we are working to perfect a line of CBD-infused skin care lotion. Providing daily sun protection with broad-spectrum SPF protection and fast-absorbing retinol, our formulation will work quickly to smooth the look of fine lines while the CBD-infused moisture enrichment will not only work to plump the skin but also soothe muscle aches, relieve pain, and reduce unwanted inflammation.

11

We are developing a shelf-stable CBD product to replace traditional sweeteners for you everyday

• beverages. Using proprietary CBD

formulations our products will not alter the taste or texture of your coffee and provide a great alternative source for daily CBD intake.

12

We have in development an innovative dermatological treatment specialized to treat against atopic dermatitis and other dermatological

• conditions. Infused with our tested

pure CBD, our CaniSkin topical cream provides soothing properties along with revolutionary healing

• results. This product will be sold OTC.

Last year, the drug Dupixent, the new and leading treatment for atopic dermatitis of 2018 achieved sales of $319 million along with FDA approval.

13

Silver Sulfadiazine Cream

Silvadene

• Used to treat atopic dermatitis
• Injected subcutaneously
• Patients can experience returned dermatitis

post treatment

• The most common side effects:
• Atopic dermatitis
• Asthma:
• Chronic rhinosinusitis with nasal

polyposis

• Hypersensitivity
• Swollen blood vessels
• Eye problems
• Topical cream application
• Works through endocannabinoid system and Cox-2

inhibition to treat atopic dermatitis

• CB2 receptors in human skin are expressed in:
• keratinocytes, immune cells, sebaceous glands,

and sensory neurons

• Promotes:
• Sebum production
• Modulates pain sensation
• Suppresses keratinocyte differentiation and

proliferation

• Inhibits inflammatory response in the skin

14

• Topical cream
• FDA approved to temporarily treat cold sores/

fever blisters (herpes labialis) symptoms

• Works by blocking the virus that causes the cold

sores from entering the healthy skin cells

• Side effects: redness or swelling
• Does not cure herpes, merely prevents further

spreading, only temporary relief

Market Info

• 70% of market
• $200M in sales
• Topical cream application
• Works through endocannabinoid system system

and Cox-2 inhibition to treat cold sores and fever blister symptoms

• CB2 receptors in human skin are expressed in:
• keratinocytes, immune cells, sebaceous glands,

and sensory neurons

• Promotes:
• Sebum production
• Modulates pain sensation
• Suppresses keratinocyte differentiation and

proliferation

• Inhibits inflammatory response in the skin

15

• Prescription topical cream
• Used with other treatments to help prevent and

treat wound infections in patients with serious burns

• Works by stopping the growth of bacteria that

may infect an open wound.

• Side effects:
• Pain, burning and itching
• Skin discoloration

Silver Sulfadiazine Cream

Silvadene

• Topical cream application
• Works through endocannabinoid system to sooth

and system and Cox-2 inhibition treat wound infections and serious burns

• CB2 receptors in human skin are expressed in:
• keratinocytes, immune cells, sebaceous glands,

and sensory neurons

• Promotes:
• Sebum production
• Modulates pain sensation
• Suppresses keratinocyte differentiation and

proliferation

• Inhibits inflammatory response in the skin

16

HealthAide

Skin cream used as a nutraceutical in over 100 patients for the treatment of dermatitis, eczema, burns, and itch with patients reporting outstanding results Technologies based on the therapeutic properties of Aspartame for the treatment of pain and inflammation Wide variety of uses in both human and animal health for the treatment of pain and inflammation Formulations include topical cream, lip balm, powder and dog treats

17

• Aspartame (Asn) acts as a Cox-2 inhibitor
• Cox-2 is also known as cyclooxygenase-2 or prostaglandin-endoperoxide synthase 2. In

humans it is one of two cyclooxygenases involved in the conversion of arachidonic acid to prostaglandin H2, an important precursor of prostacyclin, which is expressed in inflammation

• Peer-reviewed publication shows Asn can reduce atopic dermatitis in animals (Journal of

Investigative Dermatology (2015) 135, 2705–2713)

• Two issued patents. (US 7.816,327 B2 US 7,288,527 B2 )
• Third patent on combination of Asn and CBD filed

HealthAide: Science

18

“The cyclooxygenase isoforms, COX-1 and COX-2, are involved in the biosynthesis of prostaglandin E2, a major prostaglandin involved in epidermal homeostasis and repair. Cancer originating in the epidermis can develop when keratinocyte proliferation and apoptosis become dysregulated, resulting in sustained epidermal

• hyperplasia. COX-2 inhibitors, which demonstrate significant in vivo selectivity relative to COX-1, suppress both

ultraviolet-induced epidermal tumor development and progression, suggesting that prostaglandin regulation of keratinocyte biology is involved in the pathogenesis of epidermal neoplasia. In this study, we characterized the expression of COX-1 and COX-2, as well as keratinocyte proliferation, differentiation, and apoptosis, following acute ultraviolet irradiation in the hairless SKH-1 mouse. Following acute ultraviolet exposure, COX-2 expression was predominantly induced in the basal keratinocyte layer coincident with an increase in keratinocyte proliferation and apoptosis. The role of COX-2 was further evaluated using a selective COX-2 inhibitor, SC-791, as well as the traditional nonsteroidal COX inhibitor, indomethacin. Following acute ultraviolet irradiation, inhibition of COX-2 with either inhibitor decreased epidermal keratinocyte proliferation. Likewise, keratinocyte apoptosis was increased with COX-2 inhibition, particularly in the proliferating basal keratinocyte

• layer. There was also a modest inhibition of keratinocyte differentiation. These data suggest that COX-2

expression is probably necessary for keratinocyte survival and proliferation occurring after acute ultraviolet irradiation.

We hypothesize that selective COX-2 inhibition, as described herein, may lead to enhanced removal of ultraviolet-damaged keratinocytes, thereby decreasing malignant transformation in the epidermis.”

• The Journal of Investigative Dermatology, U.S. National Library of Medicine

U.S. Library of Medicine

19

• Dual mechanism of action
• Targets:
• Cox-2 enzyme
• CB2 receptor in skin
• Indications:
• Atopic dermatitis (eczema)
• Pain
• Actinic keratosis (skin cancer)
• Burns
• Non-atopic dermatitis (rash; itch)

Asn/CBD Combination Treatment of Inflammatory Skin Diseases

20

Clinical Trials

Objective – Preliminary Assessment of Safety & efficacy of CBD/Asn lotion for treatment of atopic dermatitis (eczema) Study Organization:

• Applied Biology Inc, Newport Beach, CA
• Coordinator: Andy Goren M.D.

Study Protocol:

• Investigational cosmetic ingredient (CBD)
• Double-blinded placebo controlled
• 60 patients – topical dose at least 2x per day
• End point – proportion of success in ESI score at 29 days

21

Tested Pure

CBD Isolate tested by Botanacor, based out of Denver, Colorado.

• 0.00% THC, THCa, CBDa, CBN, CBG
• 100% Cannabinoid
• Free from foreign matter

Testing concluded that our CBD Isolate is free from all Residual Solvents and Microbial Contaminants.

• Propane, Butane, Pentane, Ethanol,

Acetone, Isopropyl Alcohol, Benzene, Toluene, and Xylenes.

• No Aerobics, Coliforms, Yeast and

Molds, E.coli, or Salmonella.

• Only Heptanes were found at a rate of

273 per million.

22

15

We plan to open 50 medical clinics throughout Florida by 2022.

• 10 clinics in 2020
• 15 clinics in 2021
• 20 clinics in 2022

Based on our research, each clinic is approximately 1000 square feet and will cost $75K to open with inventory.

• 10 clinics = $200K monthlyrevenue
• 25 clinics = $500K monthlyrevenue
• 50 clinics = $1M monthlyrevenue

Brick & Mortar

Our Clinic Division

23

Benefits of Clinics

Traffic to see Doctor Access to Patient Trials Cross to Sell Products

24

We are building a robust e-commerce platform designed to connect CBD Brands directly to consumers. We plan to utilize our platform to drive sales, educate customers and build brand loyalty. Customers will find a trusted resource for thelatest industry trends and news. We plan to leverage our website with a social media presence across multiple platforms designed to leverage product reviews into increase brand loyalty/recognition and sales.

Cutting-Edge E-Commerce Store

25

CBD Brands Team

BrianJohn

CEO Doug McKinnon CFO 26

• Dr. Glynn Wilson

Chairman Rich Miller COO

• Dr. Hector Alila

Director

Tim Glynn Director

Christopher Melton Director

For the past 20 years, Brian has been an investor and global advisor tocompanies around the globe. He is the Founder of a highly successful financial consulting firm specializing in assisting emerging growth companies primarily in the sub- $100 million space and has worked with hundreds

• f

companies in dozens of countries over the last 25 years. He also serves on the board of directors of The Learning Center at the Els Center of Excellence–a school for children with autism in Jupiter,Florida.

CBD Brands Team

• Mr. McKinnon's 35 year professional career includes financial,

advisory and operation experience across a broad spectrum of industries, including

• il

& gas, technology, cannabis and

• communications. He has held C-level positions in private and

public sectors, which include CEO & Chairman of an American- Stock-Exchange traded company, VP - Chief Administrative Officer of a $12-billion market cap NASDAQ company which raised $2.2 billion, CFO of several publicly-held US, Canadian and Australian companies, and CEO/CFO of various other private enterprises. As an entrepreneur, Mr. McKinnon has been involved in organizations ranging venture capital start-ups to institutionally backed public companies. Mr. McKinnon has significant experience with merger, acquisition and turnaround.

• Mr. McKinnon has a MBA & BBA from Texas Christian
• University. He spent nine years as a CPA with PWC in their

S.E.C Communications and Oil & Gas Practice Sections.

Brian John CEO Doug McKinnon CFO

27

Glynn brings an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech

• rganizations. He was

formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals, Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals, and Founder, CEO and Chairman of TapImmune Inc. for 12 years which became Marker Therapeutics through merger. At TapImmune he licensed cancer vaccine technology platforms and established the clinical pipeline.

CBD Brands Team

• Dr. Glynn Wilson

Chairman

28 Since 2000, Rich has managed

• perations

for a financial consulting firm specializing in assisting emerging growth

• companies. He was a Co-Founder of SimplePons, Inc. a mobile app

and physical coupon book developer. Mr. Miller was COO and Co- Founder of Teeka Tan Products, Inc. from 2002 until 2008. Prior to the company sale he helped design and create a full line of suncare products, including SPF lotions, oils and after sun. He managed the deal from concept to sale of the company.

Rich Miller COO

CBD Brands Board

Came

• ut
• f

Lehman Brothers with a deep and diverse background including; 25 years on Wall Street. Mr. Glynn is an entrepreneur with significant executive experience and management in Finance, Hedge Funds, Capital Markets, International Sales and Marketing, Operations, Product Development, Acquisitions and Integrations and Divestures. He's a Team Builder running multiple organizations in both domestic and international markets. Mr Glynn has built, funded and sold multiple businesses (public & private). He is a seasoned Advisor to C-Level Executives, High Net Worth Individuals, Institutions, Trusts, Family Offices, Public and Private Enterprises, and Hedge Funds throughout the US and the world with billions in the markets.

• Dr. Alila brings 30 years of scientific experience in product

development and management. He is the Founder and CEO of Esperance Pharmaceutical, Inc. Prior to that he served as Sr. VP of Drug Development at Protalex, Inc., where he led the development of a drug currently in clinical trials for treatment of autoimmune diseases. He was VP of Product Development at Cell Pathways, Inc. where he was responsible for the development of cancer drugs. He was the Director of Biology & Pharmacology at GeneMedicine, Inc., where led the development of gene medicines.

Tim Glynn Director

• Dr. Hector Alila

Director

29

Chris Melton was a Senior Real Estate Equity Analyst at RREEF Funds in Chicago from 1995 to 1997. From 2000 to 2008, Mr. Melton was a Portfolio Manager for Kingdon Capital Management ("Kingdon") in New York City, where he ran in excess of $1 Billion book in media, telecom, and Japanese investment. Mr. Melton opened Kingdon's office in Japan, where he set up a Japanese research company. From 1997 to 2000, Mr. Melton served as a Vice President at JPMorgan Investment Management as an equity research analyst, where he helped manage $ 1 Billion plus in REIT funds under management.

• Mr. Melton is Principal and co-

founder of Callegro Investments, a specialist land investor. He currently serves on several Public and Private Boards as well as Chairman of the Audit Committee of a NASDAQ listed company.

Christopher Melton Director

CBD Brands Board

30

• According to a new estimate from leading cannabis industry analysts Brightfield Group, the

hemp-derived CBD market could hit $22 billion by2022.

• CBD, a non-psychoactive cannabinoid found in cannabis, has surged in popularity in recent

years–Brightfield Group is projecting 55% CAGR for the industry and sales from 2017 to 2018 increased more than 50%.

• A sweeping agriculture bill passed in December, 2018, by Congress legalizes hemp

cultivation at the federal level and should help clear the path for further development and sale of CBDProducts.

• We believe we are well positioned in the marketplace to capitalize on this emerging industry.

31

The Market Is About To Bloom

• 76 percent of consumers said they would be

likely to try a legal therapeutic product infused with cannabis

• 80 percent of consumers believe cannabis
• ffers health benefits.
• Cannabis’ appeal crosses demographic lines:

young and old, male and female.

• Consumers are open to established companies

entering this space.

• Consumers are most likely to try cannabis in

foods, supplements, and cosmetics or skincare.

The Next Gold Rush

CBD

32

*according to ATKearney

CBDbrands.com • +1(561) 325-0482 •info@CBDbrands.com

33